Undisclosed dual CD73/PD-1 targeting DFC / Cidara Therap - LARVOL DELTA

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "First-in-class CD73/PD-1 targeting DFC is comprised of a multivalent conjugate of a small molecule CD73 inhibitor stably linked to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide....Multispecific DFC demonstrated potent inhibition of tumor growth in a humanized mouse model and was more potent than PD-1 monotherapy."

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire) - "Cidara Therapeutics, Inc...announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara also presented new preclinical data on CBO421...'Dual inhibition of both CD73 and PD-1 checkpoint pathways with a single DFC contributed to significant tumor growth reduction, highlighting the potential clinical benefits of this first-in-class multi-specific inhibitor derived from our Cloudbreak platform.'...Cidara is currently advancing its dual CD73/PD-1 inhibitor DFC and CBO421 in preclinical studies. The company plans to file an investigational new drug (IND) application in mid-2024 for CBO421."

IND • Preclinical • Solid Tumor

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire) - "Cidara Therapeutics...announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland."

Preclinical • Solid Tumor